Holocene Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Holocene Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.29M	Buy	+163,732	New	+$3.81M	0.01%	447
2023 Q4	–	Sell	-1,204,538	Closed	-$6.4M	–	699
2023 Q3	$6.4M	Sell	1,204,538 -235,498	-16%	-$2M	0.03%	347
2023 Q2	$13.7M	Sell	1,440,036 -629,141	-30%	-$6.98M	0.06%	237
2023 Q1	$22.8M	Buy	2,069,177 +924,034	+81%	+$13.4M	0.11%	190
2022 Q4	$16.9M	Buy	1,145,143 +1,004,141	+712%	+$17.5M	0.1%	201
2022 Q3	$2.69M	Buy	+141,002	New	+$3.19M	0.02%	363

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Holocene Advisors's ARQT Position: Q2 2026 in Review

Holocene Advisors opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 163,732 shares worth $4.29M. The stake represents 0.01% of the portfolio and ranks #447 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in ARQT as recently as Q3 2023.

Holocene Advisors first reported a position in ARQT in Q3 2022 and has held it in 6 quarters since. The position peaked at $22.8M in Q1 2023. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Holocene Advisors held 163,732 shares of Arcutis Biotherapeutics worth $4.29M as of Q2 2026.
Arcutis Biotherapeutics was a new Holocene Advisors position in Q2 2026.
Arcutis Biotherapeutics made up 0.01% of Holocene Advisors's portfolio in Q2 2026, its #447 holding.
Holocene Advisors first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 6 quarters since.
Holocene Advisors's Arcutis Biotherapeutics position peaked at $22.8M in Q1 2023.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.